CKPT / Checkpoint Therapeutics: Cosibelimab Data Bolsters Case For Dual-Approval In cSCC

WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and more_horizontal

A PDUFA date of January 3, 2024 has been established by which FDA will decide upon by then whether or not cosibelimab should be approved for the treat more_horizontal

Checkpoint Therapeutics announced updated, longer-term data for cosibelimab from their pivotal trial in locally advanced and metastatic cutaneous squa more_horizontal

If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to fin more_horizontal

We are checking back in on a small developmental company called Checkpoint Therapeutics, Inc. The company is planning to submit a BLA targeting two in more_horizontal

WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and more_horizontal

Cosibelimab BLA submission to FDA for cutaneous squamous cell carcinoma is expected in late 2022, with MAA to the European Medicines Agency shortly th more_horizontal

WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and more_horizontal